Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

Exclusion Criteria

• •Other skin disease noted on physical examination that is considered by the investigator to be relevant to the outcome of the trial.
• •Subjects with acute psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, pustular, exfoliative or inverse psoriasis.
• •History of psoriasis that was unresponsive or poorly responsive to topical treatments.
• •Topical antipsoriatics are not permitted on the same body area as plaques to be treated during the 4 weeks before first treatment and during the trial.
• •Systemic treatment with antipsoriatics e.g. corticosteroids, cytostatics, retinoids, dimethylfumarate, apremilast in the 3 months before first treatment and during the trial.
• •Systemic treatment with biological treatments: rituximab within 12 months, ustekinumab or secukinumab within 6 months before first treatment and during the trial.
• •Systemic treatment with biological treatments within 3 months before first treatment and during the trial.
• •Systemic treatment with any other biological treatments within the period of 5 half-lives of the biological before first treatment and during the trial.
• •UV-therapy or extensive exposure to UV radiation or sunlight within 4 weeks before first treatment and during the trial.
• •Treatment with concomitant medication that may affect and provoke or aggravate psoriasis, unless on a stable dose for 3 months before trial medication initiation.
• •Any other topical medication on the plaques to be treated during the trial.
• •Clinically significant abnormal vital signs (blood pressure, and pulse) at screening (V1).
• •History/symptoms of a clinically significant illness before first treatment (past 5 years) and during the trial that in the investigator's opinion may place the subject at risk.
• •History/symptoms of a clinically significant illness before first treatment (past 5 years) and during the trial that in the investigator's opinion may influence the trial outcome.
• •Other clinically significant abnormal laboratory results.